Please login to the form below

Not currently logged in
Email:
Password:

Gliadel

This page shows the latest Gliadel news and features for those working in and with pharma, biotech and healthcare.

Glioblastomas - a personalised future?

Glioblastomas - a personalised future?

Even agents approved within the last decade - a wafer formulation of carmustine (Gliadel) for implantation into the post-surgical tumour cavity and temozolomide (Temodal), an oral imidazotetrazine derivative of the alkylating

Latest news

  • Early 2013 sees drug filings, launches and approvals in Japan Early 2013 sees drug filings, launches and approvals in Japan

    Eisai and Nobelpharma have launched brain cancer drug Gliadel (carmustine), which becomes the only sustained-release formulation approved for intracranial implantation in Japan. ... Nobelpharma acquired manufacturing and marketing rights to Gliadel from

  • Back on track

    Gliadel wafers are implanted in the tumour cavity created in the brain after surgical removal and release carmustine slowly, directly to the tumour site. ... Gliadel has been shown to prolong the survival of patients significantly compared with those

  • New accounts: October

    Dermatology. Life. Link Pharmaceuticals. Gliadel implant. Oncology. Addjuice. Napp Pharmaceuticals. New product.

  • New accounts: November

    Pulsar Healthcare Communications. Link Pharmaceuticals. Gliadel implant. Oncology. Addjuice. Mayne Pharma.

  • New accounts: September

    Link Pharmaceuticals. Gliadel implant. Oncology. Addjuice. Napp Pharmaceuticals. New product. Analgesia.

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics